Cargando…

Pharmacokinetics, pharmacodynamics and efficacy of novel FabI inhibitor AFN-1252 against MSSA and MRSA in the murine thigh infection model

AFN-1252, a new antimicrobial agent, specifically and potently inhibits fatty acid synthesis in Staphylococcus aureus. We characterized in vivo pharmacokinetic and pharmacodynamic profiles of AFN-1252 administered orally to neutropenic mice inoculated in thighs (∼10(6) CFU) with methicillin-suscepti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Banevicius, Mary A, Kaplan, Nachum, Hafkin, Barry, Nicolau, David P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Maney Publishing 2013
Materias:	Antimicrobial Original Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3558988/ https://www.ncbi.nlm.nih.gov/pubmed/23433441 http://dx.doi.org/10.1179/1973947812Y.0000000061

Ejemplares similares

In vitro activity (MICs and rate of kill) of AFN-1252, a novel FabI inhibitor, in the presence of serum and in combination with other antibiotics
por: Kaplan, Nachum, et al.
Publicado: (2013)

Activity of AFN-1252, a novel FabI inhibitor, against Staphylococcus aureus in an in vitro pharmacodynamic model simulating human pharmacokinetics
por: Tsuji, Brian T, et al.
Publicado: (2013)

Mutations upstream of fabI in triclosan resistant Staphylococcus aureus strains are associated with elevated fabI gene expression
por: Grandgirard, Denis, et al.
Publicado: (2015)

Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Target Attainment Analyses for Dalbavancin in Pediatric Patients
por: Carrothers, Timothy J., et al.
Publicado: (2022)

Correlating drug–target kinetics and in vivo pharmacodynamics: long residence time inhibitors of the FabI enoyl-ACP reductase
por: Daryaee, Fereidoon, et al.
Publicado: (2016)

Nonactive-Site Mutations in S. aureus FabI That Induce Triclosan Resistance
por: Demissie, Robel, et al.
Publicado: (2020)

Molecular Modelling Study and Antibacterial Evaluation of Diphenylmethane Derivatives as Potential FabI Inhibitors
por: Hasan, Shaima, et al.
Publicado: (2023)

193. Comparison of Survival for MSSA and MRSA Endocarditis
por: Kanyo, Emese, et al.
Publicado: (2019)

Proteomic profiling of the endogenous peptides of MRSA and MSSA
por: Tu, Haixia, et al.
Publicado: (2021)

Implementation of permeation rules leads to a FabI inhibitor with activity against Gram-negative pathogens
por: Parker, Erica N., et al.
Publicado: (2019)

Pharmacokinetics and Safety of Ceftobiprole in Pediatric Patients
por: Rubino, Christopher M., et al.
Publicado: (2021)

Staphylococcus aureus but not Listeria monocytogenes adapt to triclosan and adaptation correlates with increased fabI expression and agr deficiency
por: Nielsen, Lene Nørby, et al.
Publicado: (2013)

Meleagrin, a New FabI Inhibitor from Penicillium chryosogenum with at Least One Additional Mode of Action
por: Zheng, Chang Ji, et al.
Publicado: (2013)

Pharmacophore and Molecular Docking Guided 3D-QSAR Study of Bacterial Enoyl-ACP Reductase (FabI) Inhibitors
por: Lu, Xiaoyun, et al.
Publicado: (2012)

Drug-likeness prediction of designed analogues of isoniazid standard targeting FabI enzyme regulation from P. falciparum
por: Pandey, Anil Kumar, et al.
Publicado: (2019)

Relationship Between Real-time TDM-guided Pharmacodynamic Target Attainment of Continuous Infusion Beta-lactam Monotherapy and Microbiologic Outcome in the Treatment of Critically Ill Children With Severe Documented Gram-negative Infections
por: Gatti, Milo, et al.
Publicado: (2023)

Carbapenemase-producing Pseudomonas aeruginosa –an emerging challenge
por: Tenover, Fred C., et al.
Publicado: (2022)

Pyrazolyl Thioureas and Carbothioamides with an NNSN Motif against MSSA and MRSA
por: Delpe-Acharige, Anjana, et al.
Publicado: (2021)

Efficiency of Antimicrobial Photodynamic Therapy with Photodithazine(®) on MSSA and MRSA Strains
por: Souza, Beatriz Müller Nunes, et al.
Publicado: (2021)

Safety, Efficacy and Pharmacokinetics of Anidulafungin in Patients 1 Month to <2 Years of Age With Invasive Candidiasis, Including Candidemia
por: Roilides, Emmanuel, et al.
Publicado: (2020)

Simulated Comparison of a Bayesian Clinical Decision Support System Versus Standard of Care For Achieving Gentamicin Pharmacokinetic Targets in Neonates
por: Yu, Collin Z., et al.
Publicado: (2020)

Directed carbapenemase testing is no longer just for Enterobacterales: cost, labor, and workflow assessment of expanding carbapenemase testing to carbapenem-resistant P. aeruginosa
por: Gill, Christian M., et al.
Publicado: (2023)

Pharmacokinetic/pharmacodynamic analysis of teicoplanin in patients with MRSA infections
por: Matsumoto, Kazuaki, et al.
Publicado: (2016)

Characterization of Heterogeneous MRSA and MSSA with Reduced Susceptibility to Chlorhexidine in Kuwaiti Hospitals
por: Vali, Leila, et al.
Publicado: (2017)

Detection of Staphylococcus aureus (MRSA/MSSA) in surfaces of dental medicine equipment
por: Gonçalves, Eva, et al.
Publicado: (2020)

Ligand‐ and Structure‐Based Approaches of Escherichia coli FabI Inhibition by Triclosan Derivatives: From Chemical Similarity to Protein Dynamics Influence
por: Kronenberger, Thales, et al.
Publicado: (2019)

Safety, Tolerability and Pharmacokinetics of MEDI8897, an Extended Half-life Single-dose Respiratory Syncytial Virus Prefusion F-targeting Monoclonal Antibody Administered as a Single Dose to Healthy Preterm Infants
por: Domachowske, Joseph B., et al.
Publicado: (2018)

Spa Diversity among MRSA and MSSA Strains of Staphylococcus aureus in North of Iran
por: Shakeri, Fatemeh, et al.
Publicado: (2010)

Control of MSSA and MRSA in the United States: protocols, policies, risk adjustment and excuses
por: Kavanagh, Kevin T.
Publicado: (2019)

Development of Antibacterial Protective Coatings Active against MSSA and MRSA on Biodegradable Polymers
por: Rezić, Iva, et al.
Publicado: (2021)

Baloxavir Marboxil Single-dose Treatment in Influenza-infected Children: A Randomized, Double-blind, Active Controlled Phase 3 Safety and Efficacy Trial (miniSTONE-2)
por: Baker, Jeffrey, et al.
Publicado: (2020)

Neutropenic Rat Thigh Infection Model for Evaluation of the Pharmacokinetics/Pharmacodynamics of Anti-Infectives
por: Yedle, Randhir, et al.
Publicado: (2023)

Laboratory-Based and Point-of-Care Testing for MSSA/MRSA Detection in the Age of Whole Genome Sequencing
por: van Belkum, Alex, et al.
Publicado: (2018)

Incidence of biofilm formation among MRSA and MSSA clinical isolates from hospitalized patients in Israel
por: Leshem, Tamar, et al.
Publicado: (2022)

Comparison of Different Label-Free Raman Spectroscopy Approaches for the Discrimination of Clinical MRSA and MSSA Isolates
por: Pistiki, Aikaterini, et al.
Publicado: (2022)

Ventilator-Associated Pneumonia Due to MRSA vs. MSSA: What Should Guide Empiric Therapy?
por: Colaneri, Marta, et al.
Publicado: (2022)

An Iterative Approach Guides Discovery of the FabI Inhibitor Fabimycin, a Late-Stage Antibiotic Candidate with In Vivo Efficacy against Drug-Resistant Gram-Negative Infections
por: Parker, Erica N., et al.
Publicado: (2022)

Murine Thigh Microdialysis to Evaluate the Pharmacokinetic/Pharmacodynamic Integration of Cefquinome Against Actinobacillus pleuropneumoniae
por: Zhang, Longfei, et al.
Publicado: (2020)

Pharmacokinetics and pharmacodynamics of enrofloxacin treatment of Escherichia coli in a murine thigh infection modeling
por: Liu, Xuesong, et al.
Publicado: (2021)

Treatment of Spent Pickling Solutions by Diffusion Dialysis Using Anion-Exchange Membrane Neosepta-AFN
por: Bendová, Helena, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5j1q2ljp5ulc6ubckju3s3h80e